United States, Sept. 25 -- The U.S. Food and Drug Administration authorized marketing of the Essilor Stellest eyeglass lenses to correct myopia, commonly referred to as nearsightedness, with or without astigmatism and to slow the progression of the disease in children 6 to 12 years old at the initiation of treatment.Strengthening the foundation of our nation's health begins at childhood. This authorization reflects the FDA's unwavering commitment to addressing chronic diseases and advancing safe, effective, and innovative medical devices that improve the lives of young Americans. According to the National Eye Institute, several studies indicate that the prevalence of myopia is increasing in the U.S. and worldwide, and researchers project th...